Cyclerion Therapeutics
Cyclerion Therapeutics, founded in 2019, is a biopharmaceutical company focused on developing treatments for serious diseases, including novel soluble guanylate cyclase stimulators like praliciguat and olinciguat.
Company Overview
Cyclerion Therapeutics, founded in 2019, is an independent, publicly traded biopharmaceutical company headquartered in Cambridge, MA. It is dedicated to developing treatments for serious diseases, focusing on novel clinical-stage assets and various research stage molecules. The company aims to provide innovative medicines for patients who need new treatment options.
Pipeline and Products
Cyclerion Therapeutics' portfolio features novel soluble guanylate cyclase (sGC) stimulators, including praliciguat and olinciguat. Praliciguat, a systemic sGC stimulator, has been exclusively licensed to Akebia for development in treating rare kidney disease. Olinciguat, a vascular sGC stimulator, shows potential applications in cardiovascular diseases. The company is committed to advancing these assets through clinical evaluations and partnerships.
Collaborations and Partnerships
To maximize value and accelerate global patient access, Cyclerion Therapeutics evaluates activities aimed at enhancing shareholder value. These include collaborations, licenses, mergers, acquisitions, and targeted investments. The 'best-owner' approach ensures that compounds are independently developed and commercialized or through partner organizations.
Mission and Vision
The mission of Cyclerion Therapeutics is to develop innovative medicines for patients in desperate need of new treatment options. The company leverages a diverse cross-disciplinary network of external advisors and experts to advance its programs, ensuring that scientific and clinical expertise guide each stage of development.